Hangzhou Jinshennuo Biopharmaceutical

Hangzhou Jinshennuo Biopharmaceutical Co., Ltd. (SGP) is a clinical-stage biotechnology company specializing in advanced liposomal drug delivery systems (DDS). The company has pioneered the 'Ginposome' platform, a first-in-class technology that utilizes natural ginsenosides as membrane stabilizers and active targeting ligands instead of animal-derived cholesterol. SGP's therapeutic pipeline includes Ginposome-Paclitaxel (G-PTX), which is in the IND stage for oncology indications such as gastric and breast cancers, alongside pre-clinical programs like Ginposome-Docetaxel and Ginposome-Cabazitaxel. In addition to its pharmaceutical pipeline, the company develops and commercializes a wide range of liposomal and ginposomal nutraceutical ingredients, including glutathione, NMN, and Coenzyme Q10.